H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) on October 21 with a $40 price target.

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

The analyst cited the promising clinical developments in the company’s portfolio, stating that the recent presentation at the ESMO meeting showed the efficacy of  rinatabart sesutecan (Rina-S)  for the treatment of endometrial cancer. It demonstrated notable response rates in patients, irrespective of OFRα expression levels.

According to the analyst, these results are especially encouraging when compared to present treatments that show lower overall response rates, including the combination of ELAHERE and Keytruda.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.